Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service

JAMA. 2014 Feb 26;311(8):793-4. doi: 10.1001/jama.2014.148.
No abstract available

MeSH terms

  • Community Participation
  • Consumer Product Safety / legislation & jurisprudence
  • Genetic Predisposition to Disease*
  • Genetic Testing / legislation & jurisprudence*
  • Genetic Testing / standards
  • Government Regulation*
  • Humans
  • Marketing of Health Services / legislation & jurisprudence*
  • Patient Advocacy
  • Polymorphism, Single Nucleotide
  • Risk
  • United States
  • United States Food and Drug Administration